

FINANCIAL EXPRESS

11

इंडियन बैंक  **Indian Bank**

Corporate Office,
Recovery Department,
254 -260, Avvai Shanmugam Salai,
Royapettah, Chennai - 600014

SALE OF NON PERFORMING FINANCIAL ASSETS

It is proposed to put on sale of Non-Performing Financial Assets of the Bank on individual / pool basis to the eligible purchasers, in terms of the guidelines issued by RBI. Proposal from interested ARCs / Banks / NBFCs / FIs are invited. For more details and to peruse the proposal for sale, please visit our website www.indianbank.in or contact The Assistant General Manager, Recovery Department, Corporate Office, Chennai, at the address given above. (Land Line **044-28134580, 28134576**) The proposal for sale will be ported in our Bank's Website.

Deputy General Manager (Recovery)

NMDC Steel Limited
Post-Nagamar(Bastar)Chhattisgarh-494001
CIN:L27310CT2015GO1001618.

E-mail: nalcontracts@nmdc.co.in; gajandrasethiya@nmdc.co.in; csn@nmdc.co.in

OPEN TENDER ENQUIRY

NMDC Steel Limited, Nagarnar, invites sealed tenders in two bid system for the following:
Name of Work: Design, Supply, Installation, Testing and Commissioning of additional 01 no. of 140 MT Electronic in Motion Rail Weighbridge Tender No & Date: **NSL/Nagarnar/Contracts/1425-26/ET/22[Weighbridge]** Dated: 11.10.2025, last date & Time for submission of offers as 03.11.2025 by 02.30 PM

Tender documents can be downloaded from websites www.nmdc.co.in or www.eprocure.gov.in or www.mstcecommerce.com/eprochome/nmdc/buyer_login.jsp

HOD(Contracts)

AMIN TANNERY LIMITED

CIN No: L19115UP2013PLC055834 | GSTIN NO 09AALCA4722D1ZU
Registered Office: 15/288 C.Civil Lines , Kanpur-208001 (India)+91 7380795333
Website: www.amintannery.in E-mail: mail@amintannery.in

NOTICE TO SHARE HOLDERS REGARDING CAMPAIGN- "SAKSHAM NIVESHAK"

Dear Shareholders,

In view of the initiative of MCA, under 100 days Campaign "Saksham Niveshak", shareholders are requested to update their KYC details, including PAN, nomination details, contact information (postal address and mobile number), bank account details, and specimen signature, with the Company or its Registrar & Transfer Agent -Klin Technologies Limited ("KFIN"), to ensure seamless communication and efficient processing of shareholder-related activities.

This campaign is a proactive initiative to assist shareholders in updating their KYC details, bank mandates, nominee information, and contact details.

We urge all shareholders to take timely action to avoid the transfer of their shares and dividends to the Investor Education and Protection Fund Authority (IEPFA), as mandated under applicable regulations after the completion of seven (7) years from the date of transfer to Unpaid Dividend Account.

During this Campaign all the shareholders who have those who are required to update their KYC and Nominee Details have any issues / queries related to unpaid /unclaimed dividend and shares may write to the Companies Registrar and Transfer Agent (RTA) i.e. at their office at Selenium Tower-B plot NO 31732, GACHIBOWLI Financial District Nanakramguda, Serilingampally Telangana, Hyderabad-500032. E-mail: Einward.ris@kfintech.com Web: www.kfintech.com shareholders are requested to download KYC forms from the Company website at the path <http://www.amintannery.in/KYC.asp>.

By Order of the Board
Sd/-
Sharad Chandra Shukla
Company secretary

Place: Kanpur
Date : 10.10.2025

SAYAJI HOTELS (PUNE) LIMITED
CIN : L55204GJ2018PLC161133
Regd. Office : Near Kala Ghoda Circle, Sayajiganj, Vadodara, Gujarat-390020 IN
Tel. No.: 0731-4006666 | Email Id : cs@shlpune.com | Website : www.shlpune.com

Extract of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year ended 30th September 2025 (₹ in Lakhs except figures of EPS)

S. No.	Particulars	Standalone			Consolidated		
		Quarter Ended 30.09.2025 (Unaudited)	Quarter Ended 30.09.2024 (Unaudited)	Half Year Ended 30.09.2025 (Unaudited)	Quarter Ended 30.09.2025 (Unaudited)	Quarter Ended 30.09.2024 (Unaudited)	Half Year Ended 30.09.2025 (Unaudited)
1	Total Income from Operation (Net)	1883.30	1,847.76	3,784.95	1,883.30	1,847.76	3,784.95
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items)	609.66	573.65	1,247.74	602.99	564.23	1,239.33
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items)	609.66	573.65	1,247.74	602.99	564.23	1,239.33
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items)	538.32	426.05	1,000.28	533.40	419.08	990.97
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	539.76	421.08	1,000.12	534.84	414.11	990.81
6	Equity Share Capital	304.66	304.66	304.66	304.66	304.66	304.66
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-	-
8	Earnings Per Share (of ₹ 10/- each) (for continuing & discontinued operations) Basic: Diluted:	17.67 17.67	13.98 13.98	32.83 32.83	17.51 17.51	13.76 13.76	32.53 32.53

Note: The above is an extract of the detailed format of Financial Results for the Quarter and Half Year ended 30th September, 2025 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the Quarter and Half Year ended 30th September, 2025 are available on the website of Stock Exchange at www.bseindia.com and Company's website at www.shlpune.com and the same can be accessed by scanning the QR Code attached below.

Place : **Indore**, Date : **10.10.2025**

By the Order of the Board
For **Sayaji Hotels (Pune) Limited**
Sd/-
Abhay Chintaman Chaudhari
Chairman

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. **NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.**

INITIAL PUBLIC OFFERING OF EQUITY SHARES ON THE MAIN BOARD OF THE BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE"), AND TOGETHER WITH BSE, THE "STOCK EXCHANGES") IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS").

PUBLIC ANNOUNCEMENT

integris
Medtech

INTEGRIS MEDTECH LIMITED

(FORMERLY KNOWN AS INTEGRIS HEALTH PRIVATE LIMITED)

Our Company was incorporated as 'Integrus Health Private Limited' as a private limited company under the Companies Act, 1956 pursuant to certificate of incorporation dated April 25, 2008, issued by Assistant Registrar of Companies, National Capital Territory of Delhi and Haryana at Delhi. Our Company changed its name to 'Integrus Medtech Private Limited', pursuant to which a fresh certificate of incorporation dated June 30, 2025 was issued by the Assistant Registrar of Companies, Central Processing Centre. Further, our Company was converted into a public limited company pursuant to the resolution passed by our Board of Directors on July 16, 2025, and special resolution passed by our Shareholders on August 1, 2025 and the name of our Company was changed to 'Integrus Medtech Limited' and consequently, a fresh certificate of incorporation dated August 8, 2025 was issued by the Assistant Registrar of Companies, Central Processing Centre. For further details in relation to the changes in the name and registered office of our Company, see "History and Certain Corporate Matters" on page 305 of the draft red herring prospectus dated October 9, 2025 ("DRHP").

Corporate Identity Number: U85110DL2008PLC177230

Registered Office: 1st Floor, Metro Tower LSC, M.O.R Land, New Rajinder Nagar, New Delhi, 110 060 Delhi, India; **Corporate Office:** Unit 702 & 703, BPTP Capital City, Sector 94, Noida 201 301, Uttar Pradesh, India

Contact person: Darpan Batra, Group General Counsel, Company Secretary and Compliance Officer, Tel.: +91 120 4531422; E-mail: investors@integrismedtech.com; Website: www.integrismedtech.com

PROMOTERS OF OUR COMPANY: EVERCURE HOLDINGS PTE. LTD., MEDICORE HOLDINGS PTE. LTD., GURMIT SINGH CHUGH AND PUNITA SHARMA

INITIAL PUBLIC OFFERING OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹1 EACH ("EQUITY SHARES") OF INTEGRIS MEDTECH LIMITED (FORMERLY KNOWN AS INTEGRIS HEALTH PRIVATE LIMITED) (OUR "COMPANY" OR THE "COMPANY") FOR CASH AT A PRICE OF ₹[•] PER EQUITY SHARE (INCLUDING A PREMIUM OF ₹[•] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹[•] MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹9,250.00 MILLION (THE "FRESH ISSUE") AND AN OFFER FOR SALE (THE "OFFER FOR SALE") OF UP TO 21,674,531 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION COMPRISING UP TO 15,174,251 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY EVERCURE HOLDINGS PTE. LTD., UP TO 3,250,140 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY GURMIT SINGH CHUGH AND UP TO 3,250,140 EQUITY SHARES OF FACE VALUE ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY PUNITA SHARMA (COLLECTIVELY, "PROMOTER SELLING SHAREHOLDERS" AND SUCH SHARES, THE "OFFERED SHARES").

OUR COMPANY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS, MAY CONSIDER A PRE-IPO PLACEMENT OF EQUITY SHARES, AS MAY BE PERMITTED UNDER THE APPLICABLE LAW, AT ITS DISCRETION, AGGREGATING UP TO ₹1,850.00 MILLION, PRIOR TO FILING OF THE RED HERRING PROSPECTUS WITH THE ROC. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, WILL BE AT A PRICE TO BE DETERMINED BY OUR COMPANY, IN CONSULTATION WITH THE BRLMs. IF THE PRE-IPO PLACEMENT IS COMPLETED, THE AMOUNT RAISED PURSUANT TO THE PRE-IPO PLACEMENT WILL BE REDUCED FROM THE FRESH ISSUE, SUBJECT TO COMPLIANCE WITH RULE 19(2)(B) OF THE SECURITIES CONTRACTS (REGULATION) RULES, 1957, AS AMENDED. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, SHALL NOT EXCEED 20% OF THE SIZE OF THE FRESH ISSUE. PRIOR TO THE COMPLETION OF THE OFFER, OUR COMPANY SHALL APPROPRIATELY INTIMATE THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT, PRIOR TO ALLOTMENT PURSUANT TO THE PRE-IPO PLACEMENT, THAT THERE IS NO GUARANTEE THAT OUR COMPANY MAY PROCEED WITH THE OFFER OR THE OFFER MAY BE SUCCESSFUL AND WILL RESULT INTO LISTING OF THE EQUITY SHARES ON THE STOCK EXCHANGES. FURTHER, RELEVANT DISCLOSURES IN RELATION TO SUCH INTIMATION TO THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT (IF UNDERTAKEN) SHALL BE APPROPRIATELY MADE IN THE RELEVANT SECTIONS OF THE RED HERRING PROSPECTUS AND THE PROSPECTUS. THE PRE-IPO PLACEMENT SHALL BE REPORTED TO THE STOCK EXCHANGE(S), WITHIN TWENTY-FOUR HOURS OF SUCH PRE-IPO TRANSACTIONS (IN PART OR IN ENTIRETY).

THE FACE VALUE OF EQUITY SHARES IS ₹1 EACH. THE OFFER PRICE IS [•] TIMES THE FACE VALUE OF THE EQUITY SHARES. THE PRICE BAND AND THE MINIMUM BID LOT SHALL BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS, AND WILL BE ADVERTISED IN ALL EDITIONS OF [•], AN ENGLISH NATIONAL DAILY NEWSPAPER AND ALL EDITIONS OF [•], A HINDI NATIONAL DAILY NEWSPAPER (HINDI ALSO BEING THE REGIONAL LANGUAGE OF DELHI, WHERE OUR REGISTERED OFFICE IS LOCATED) EACH WITH WIDE CIRCULATION, AT LEAST TWO WORKING DAYS PRIOR TO THE BID/OFFER OPENING DATE AND SHALL BE MADE AVAILABLE TO THE STOCK EXCHANGES FOR THE PURPOSE OF UPLOADING ON THEIR RESPECTIVE WEBSITES IN ACCORDANCE WITH THE SEBI ICDR REGULATIONS.

In case of any revision in the Price Band, the Bid/Offer Period will be extended by at least three additional Working Days following such revision in the Price Band, subject to the Bid/Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company may, in consultation with the Book Running Lead Managers, for reasons to be recorded in writing, extend the Bid/Offer Period for a minimum of one Working Day, subject to the Bid/Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the Book Running Lead Managers and at the terminals of the Syndicate Members and by intimation to Self-Certified Syndicate Banks ("SCSBs"), the Designated Intermediaries and the Sponsor Banks, as applicable.

The Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations and in compliance with Regulation 6(2) of the SEBI ICDR Regulations, wherein not less than 75% of the Offer shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs") ("QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion ("Net QIB Portion"). Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds ("Mutual Fund Portion"), subject to valid Bids being received at or above the Offer Price, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds subject to valid Bids being received at or above the Offer Price. If at least 75% of the Offer cannot be Allotted to QIBs, then the entire Bid Amount (as defined hereinafter) will be refunded forthwith. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to all QIBs. Further, not more than 15% of the Offer shall be available for allocation to Non-Institutional Bidders and not more than 10% of the Offer shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. One-third of the Non-Institutional Portion shall be available for allocation to Non-Institutional Bidders with a Bid size of more than ₹0.20 million and up to ₹1.00 million and two-thirds of the Non-Institutional Portion shall be available for allocation to Non-Institutional Bidders with a Bid size of more than ₹1.00 million provided that under-subscription in either of these two sub-categories of the Non-Institutional Portion may be allocated to Non-Institutional Bidders in the other sub-category of Non-Institutional Portion in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. All potential Bidders (except Anchor Investors) are mandatorily required to participate in the Offer through the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA accounts and UPI ID in case of UPI Bidders (as defined hereinafter), as applicable, pursuant to which their corresponding Bid Amount will be blocked by the SCSBs or by the Sponsor Bank(s) under the UPI Mechanism (as defined hereinafter), as the case may be, to the extent of the respective Bid Amounts. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For details, see "Offer Procedure" beginning on page 574 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares pursuant to the Offer and has filed the DRHP dated October 9, 2025 with the SEBI and the Stock Exchanges. Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with SEBI has been made available to the public for comments, if any, for a period of at least 21 days from the date of publication of this public announcement by hosting it on the website of the Company at www.integrismedtech.com, website of the SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e., BSE and NSE at www.bseindia.com and www.nseindia.com, respectively and the websites of the BRLM, i.e., www.icicisecurities.com, www.axiscapital.co.in, https://www.citigroup.com/global/about-us/global-presence/india/disclaimer and www.iiflcapital.com, respectively. Our Company hereby invites the public to give comments on the DRHP filed with SEBI and the Stock Exchanges with respect to disclosures made in the DRHP. The public is requested to send a copy of their comments to SEBI, Group General Counsel, Company Secretary and Compliance Officer of our Company and/or the BRLMs at their respective addresses mentioned below in relation to the Offer. All comments must be received by SEBI, and/or our Company and/or the Company Secretary and Compliance Officer of our Company and/or the BRLMs in relation to the offer at their respective addresses mentioned below on or before 5.00 p.m. on the 21st day from the date of publication of this public announcement.

Investments in equity and equity-related securities involve a degree of risk and Bidders should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, Bidders must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have neither been recommended, nor approved by SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Specific attention of the Bidders is invited to "Risk Factors" beginning on page 34 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be made after the Red Herring Prospectus ("RHP") has been filed with the ROC and must be made solely on the basis of such RHP as there may be material changes in the RHP from the DRHP. The Equity Shares, when offered through the RHP, are proposed to be listed on the mainboard of BSE and NSE.

For details of the share capital and capital structure of our Company, the names of the signatories to the Memorandum of Association and the number of shares of our Company subscribed by them, please see the section titled "Capital Structure" on page 98 of the DRHP. The liability of members of our Company is limited. For details of the main objects of our Company as contained in the Memorandum of Association, please see the section titled "History and Certain Corporate Matters" on page 305 of the DRHP.

BOOK RUNNING LEAD MANAGERS				REGISTRAR TO THE OFFER
				
ICICI Securities Limited ICICI Venture House Appasaheb Marathe Marg Prabhadevi, Mumbai 400 025 Maharashtra, India Tel.: +91 22 6807 7100 Email: integris ipo@icicisecurities.com Website: www.icicisecurities.com Investor Grievance ID: customercare@icicisecurities.com Contact Person: Tanya Tiwari/ Ramesh Vaswana SEBI Registration No.: INM000011179	Axis Capital Limited 1 st Floor, Axis House Pandurang Budhkar Marg, Worli Mumbai 400 025 Maharashtra, India Tel.: + 91 22 4325 2183 E-mail: integris.ipo@axiscap.in Website: www.axiscapital.co.in Investor Grievance ID: complaints@axiscap.in Contact Person: Jigar Jain SEBI Registration No.: INM000012029	Citigroup Global Markets India Private Limited First International Financial Centre (IFIC) 1202, 12 th Floor, G-Block Bandra Kurla Complex, Bandra East Mumbai 400 098 Maharashtra, India Tel.: +91 22 6175 9999 E-mail: integrismedtech.ipo@citigroup.com Investor Grievance ID: investors.cgmib@citigroup.com Website: https://www.citigroup.com/global/about-us/global-presence/india/disclaimer Contact Person: Adarsh Agarwal SEBI Registration No.: INM000010718	IIFL Capital Services Limited (formerly known as IIFL Securities Limited) 24 th Floor, One Lodha Place Senapati Bapat Marg, Lower Parel (West) Mumbai 400 013 Maharashtra, India Tel.: +91 22 4646 4728 E-mail: integris.ipo@iiflcap.com Investor Grievance ID: ig.ib@iiflcap.com Website: www.iiflcapital.com Contact Person: Mansi Sampat/ Pawan Jain SEBI Registration No.: INM000010940	KFin Technologies Limited Selenium Tower B, Plot No. 31 and 32 Financial District, Nanakramguda Serilingampally Hyderabad - 500 032 Telangana, India Tel.: +91 40 6716 2222 E-mail: integris.ipo@kfintech.com Investor Grievance ID: einward.ris@kfintech.com Website: www.kfintech.com Contact Person: M. Murali Krishna SEBI Registration No.: INR000000221

All capitalised terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

Place: New Delhi
Date: October 10, 2025

INTEGRIS MEDTECH LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the DRHP dated October 9, 2025 with SEBI and the Stock Exchanges. The DRHP is available on the website of the Company i.e., www.integrismedtech.com, SEBI at www.sebi.gov.in, as well as on the websites of the BRLM, i.e., ICICI Securities Limited, Axis Capital Limited, Citigroup Global Markets India Private Limited and IIFL Capital Services Limited (formerly known as IIFL Securities Limited) at www.icicisecurities.com, www.axiscapital.co.in, <https://www.citigroup.com/global/about-us/global-presence/india/disclaimer> and www.iiflcapital.com, respectively and the websites of National Stock Exchange of India Limited and BSE Limited at www.nseindia.com and www.bseindia.com, respectively. Potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risks, please see the section entitled "Risk Factors" on page 34 of the DRHP and the details set out in the RHP, when filed. Potential investors should not rely on the DRHP for making any investment decision.

This announcement does not constitute an invitation or offer of securities for sale in any jurisdiction. The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended, or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, such Equity Shares are being offered and sold (i) outside of the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) within the United States to "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act), pursuant to the private placement exemption set out in Section 4(a) of the U.S. Securities Act. There will be no public offering of the Equity Shares in the United States.

Adfactors